Once again, the FDA is de­lay­ing Bio­Marin’s he­mo­phil­ia A quest as gene ther­a­py frets sim­mer

Two years af­ter the FDA turned back Bio­Marin’s push for a land­mark ac­cel­er­at­ed ap­proval of their he­mo­phil­ia A gene ther­a­py val­rox, reg­u­la­tors are ask­ing for still more in­fo on the ther­a­py — and once again de­lay­ing any prospec­tive launch, this time in­to next year.

Buried un­der the lat­est set of ex­tend­ed da­ta from their Phase I/II tri­al of val­rox (val­oc­toco­gene rox­a­parvovec), which con­tin­ues to demon­strate its ef­fec­tive­ness in pre­vent­ing bleeds up to 6 years af­ter ini­tial treat­ment, the biotech spelled out the rea­sons why they’re shov­ing back an ex­pect­ed re­sub­mis­sion from June to Sep­tem­ber. The agency wants more da­ta and analy­sis, says the biotech, but isn’t ask­ing for any new stud­ies. And the news will like­ly en­hance some deep-seat­ed con­cerns that the FDA ap­pears to be in no rush to ap­prove any gene ther­a­py over­shad­owed by ques­tions of dura­bil­i­ty and safe­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER